A Study to Evaluate the Safety, Tolerability, Drug Levels, and Drug Effects of BMS-986326 in Participants With Atopic Dermatitis

Inclusion Criteria

• •Must have diagnosis of atopic dermatitis (AD) at least 12 months prior to screening
• •Documented history of inadequate response to treatment with topical medication for at least 4 weeks, unless topical treatments are otherwise medically inadvisable, or has required systemic therapy for control of disease
• •All the following must be present to confirm moderate-to-severe AD
• •* Eczema Area and Severity Index score ≥ 12 (at Screening and Day 1)
• •* Body Surface Area ≥ 10% (at Screening and Day 1)
• •* Validated Investigator Global Assessment for Atopic Dermatitis ≥ 3 (at Screening and Day 1)
• •* Peak Pruritus Numerical Rating Scale ≥ 4 (at Screening)